Kevin C. Halling, MD, Ph.D.

Associate Professor &Vice-Chair, Research and Development
Department of Laboratory Medicine and Pathology
Mayo Clinic

Dr. Halling is an Associate Professor and the vice-chair of research and development in the Department of Laboratory Medicine and Pathology at the Mayo Clinic.  He directs the Clinical Molecular Genetics Laboratory and co-directs the Molecular Anatomic Pathology Laboratory.  He is boarded in Anatomic and Clinical Pathology, Clinical Molecular Genetics, and Molecular Genetic Pathology.  He is a past chair of the CAP Molecular Oncology Committee. Dr. Halling received his M.D. from the Kansas University School of Medicine and did his pathology residency at the Mayo Clinic. During his residency he worked under Dr. Stephen Thibodeau on colon cancer genetics and was intimately involved in studies that were exploring the significance of microsatellite instability in sporadic colorectal cancer. Following his residency and Clinical Molecular Genetics fellowship he established a molecular diagnostics lab at Indiana University School of Medicine from 1995-1997.  He then returned to Mayo Clinic in 1998 and was a research fellow from 1998 to early 2000. During that time, he collaborated with a company known as Vysis (now part of Abbott Molecular) to develop a fluorescence in situ hybridization assay for the detection of bladder cancer. This test, commercially known as UroVysion, has been through two FDA trials and has become a popular assay for the detection of monitoring of bladder cancer. He has had continuous grant funding from Vysis/Abbott Molecular since 2000. The overall goal of these efforts has been to develop FISH assays for the detection of various types of tumor in cytology specimens. In addition to having developed UroVysion, his group has also developed clinical assays for the detection of lung cancer, pancreatobiliary malignancy, and dysplasia/adenocarcinoma in patients with Barrett’s esophagus. He is a co-investigator on several NIH grants with Dr. Kenneth Wang which are exploring the role of FISH and other biomarkers for Barrett’s esophagus (BE) patients. Dr. Halling has published over 90 peer peer-reviewed scientific articles that primarily deal with cancer genetics and the molecular diagnosis of cancer.